Department of Digestive and General Surgery, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.
Surg Endosc. 2019 Dec;33(12):4143-4152. doi: 10.1007/s00464-019-06723-z. Epub 2019 Mar 5.
In clinical practice, it is not unusual to treat oncologic patients whose tumor markers are within normal range, even with advanced cancer. The Controlling Nutritional Status (CONUT) score could provide a useful nutritional and immunological prognostic biomarker for cancer patients. In this study, we assessed the prognostic value of the CONUT score for patients with gastric cancer, including a subgroup analysis with stratification based on serum carcinoembryonic antigen (CEA) level.
We retrospectively reviewed the medical records of 368 consecutive patients who underwent curative laparoscopy-assisted gastrectomy. The prognostic value of the CONUT score was compared between patients with a low (≤ 2) and high (≥ 3) score, with propensity score matching (PSM) used to control for biasing covariates (Depth of tumor, Lymph node metastasis, pathological TNM (pTNM) stage).
Overall survival (OS) among all patients was independently predicted by the tumor stage (hazard ratio (HR): 2.231, p = 0.001), the CONUT score (HR: 2.254, p = 0.001), and serum CEA level (HR: 1.821, p = 0.025). Among patients with a normal preoperative serum CEA level, tumor stage (HR: 2.350, p = 0.007), and the CONUT score (HR: 1.990, p = 0.028) were independent prognostic factors of OS. In the high serum CEA level group, tumor size (HR: 2.930, p = 0.015) and the CONUT score (HR: 3.707, p = 0.004) were independent prognostic factors of OS.
It is advantageous to use both CEA level and the CONUT score to assess the prognosis of patients with gastric cancer, which reflect both tumor-related factors and host-related factors, respectively.
在临床实践中,治疗肿瘤标志物处于正常范围内的肿瘤患者并不罕见,即使是晚期癌症患者也是如此。控制营养状况(CONUT)评分可以为癌症患者提供一种有用的营养和免疫预后生物标志物。在这项研究中,我们评估了 CONUT 评分对胃癌患者的预后价值,包括基于血清癌胚抗原(CEA)水平的分层亚组分析。
我们回顾性分析了 368 例接受腹腔镜辅助胃癌根治术的连续患者的病历。通过倾向评分匹配(PSM)控制混杂因素(肿瘤深度、淋巴结转移、病理 TNM(pTNM)分期),比较 CONUT 评分低(≤2)和高(≥3)患者之间的预后价值。
所有患者的总生存(OS)均独立受肿瘤分期(风险比(HR):2.231,p=0.001)、CONUT 评分(HR:2.254,p=0.001)和血清 CEA 水平(HR:1.821,p=0.025)的影响。在术前血清 CEA 水平正常的患者中,肿瘤分期(HR:2.350,p=0.007)和 CONUT 评分(HR:1.990,p=0.028)是 OS 的独立预后因素。在高血清 CEA 水平组中,肿瘤大小(HR:2.930,p=0.015)和 CONUT 评分(HR:3.707,p=0.004)是 OS 的独立预后因素。
CEA 水平和 CONUT 评分均有利于评估胃癌患者的预后,分别反映肿瘤相关因素和宿主相关因素。